中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 3
Mar.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(3): 608-617

Effect of astragaloside Ⅳ on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism

DOI: 10.12449/JCH260316
  • 1.

    Laboratory of Cellular Immunity，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 2.

    Shanghai Key Laboratory of Traditional Chinese Clinical Medicine，Shanghai 201203，China

  • 3.

    Department of Pharmacy，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 4.

    Department of Liver Diseases，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

Research funding:

General Program of National Natural Science Foundation of China (82074372);

Shanghai Science and Technology Innovation Action Plan (23Y21920200);

Three-year Action Plan for Strengthening Public Health System Construction in Shanghai Municipality (GWVI-2.1.5)

More Information
  • Corresponding author: GAO Yueqiu， gaoyueqiu@hotmail.com （ORCID： 0000-0001-7276-9810）; HUANG Lingying， huanglingying@shutcm.edu.cn （ORCID： 0009-0003-4996-9138）
  • Received Date: 2025-08-24
  • Accepted Date: 2025-11-21
  • Published Date: 2026-03-25
    Abstract
  •   Objective  To investigate the liver-protecting and anti-liver fibrosis effects of astragaloside Ⅳ （AS-Ⅳ） in vitro and in vivo， as well as its mechanism of action in intervention against liver fibrosis.  Methods  In the animal experiment， C57BL/6J mice were divided into control group， model group， low-dose AS-Ⅳ （20 mg/kg） group， and high-dose AS-Ⅳ （80 mg/kg） group. The mice were given intraperitoneal injection of carbon tetrachloride for 6 weeks to induce liver fibrosis， and since week 3 of injection， the mice in the low-dose AS-Ⅳ group and the high-dose AS-Ⅳ group were given AS-Ⅳ by gavage at a dose of 20 mg/kg and 80 mg/kg， respectively. The serum levels of alanine aminotransferase （ALT） and aspartate aminotransferase （AST） were measured after 4 weeks of administration， as well as the serum levels of hyaluronic acid （HA）， laminin （LN）， procollagen Ⅲ N-terminal peptide （PⅢNP）， and collagen type Ⅳ （Col-Ⅳ）. HE staining， picrosirius red staining， and Masson staining were used to observe liver histopathology and collagen deposition； RT-qPCR was used to measure the mRNA expression levels of Acta2， Col1a1， and Col3a1 in liver tissue， and Western blot was used to measure the protein expression levels of α-smooth muscle actin （α-SMA）， collagen type Ⅲ （Col-Ⅲ）， phosphatidylinositol 3-kinase （PI3K）， phosphorylated PI3K （pPI3K）， protein kinase B （Akt）， and phosphorylated AKT （p-Akt） in liver tissue； transcriptome sequencing was performed for liver tissue to identify differentially expressed genes and perform a bioinformatics analysis. In the cell experiment， transforming growth factor-β （TGF-β） was used to induce the activation of LX-2 cells， and the PI3K inhibitor LY294002 and the PI3K activator 740 Y-P were used for intervention. The cells were divided into control group， model group， AS-Ⅳ group， LY294002 group， and AS-Ⅳ+740 Y-P group， and the cells were harvested after 36 hours of intervention. Changes in the protein expression levels of α-SMA， Col-Ⅲ， pPI3K/PI3K， and pAkt/Akt in LX-2 cells were measured， as well as changes in the relative mRNA expression levels of Acta2， Col1a1， and Col3a1. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups.  Results  In the animal experiment， compared with the model group， the AS-Ⅳ treatment group had significant reductions in the serum levels of ALT， AST， HA， LN， PⅢNP， and Col-Ⅳ （all P<0.01）， the mRNA expression levels of Acta2， Col1a1， and Col3a1 in liver tissue （all P<0.05）， and the protein expression levels of α-SMA， Col-Ⅲ， pPI3K， and pAkt （Ser473） in liver tissue （all P<0.05）. In the cell experiment， compared with the control group， the model group had significant increases in the protein expression levels of α-SMA， Col-Ⅲ， pPI3K， and pAkt （Ser473） after TGF-β induction （all P<0.05）； compared with the model group， the AS-Ⅳ group had significant reductions in the protein expression levels of α-SMA， Col-Ⅲ， pPI3K， and pAkt （Ser473） （all P<0.05）， and both the AS-Ⅳ group and the LY294002 group had significant reductions in the protein expression level of pPI3K and the relative mRNA expression levels of Acta2， Col1a1， and Col3a1 （all P<0.05）. Compared with the AS-Ⅳ group， there were significant increases in the protein expression level of pPI3K and the relative mRNA expression levels of Acta2， col1a1， and Col3a1 after 740 Y-P intervention （all P<0.05）.  Conclusion  AS-Ⅳ can inhibit hepatic stellate cell activation and improve liver fibrosis， possibly by inhibiting the PI3K/Akt signaling pathway.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    HUANG DQ, TERRAULT NA, TACKE F, et al. Global epidemiology of cirrhosis: Aetiology, trends and predictions[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 6): 388- 398. DOI: 10.1038/s41575-023-00759-2.
    [2]
    ZHANG CY, LIU S, YANG M. Treatment of liver fibrosis: Past, current, and future[J]. World J Hepatol, 2023, 15( 6): 755- 774. DOI: 10.4254/wjh.v15.i6.755.
    [3]
    TRIVEDI P, WANG S, FRIEDMAN SL. The power of plasticity-metabolic regulation of hepatic stellate cells[J]. Cell Metab, 2021, 33( 2): 242- 257. DOI: 10.1016/j.cmet.2020.10.026.
    [4]
    YIN CY, EVASON KJ, ASAHINA K, et al. Hepatic stellate cells in liver development, regeneration, and cancer[J]. J Clin Invest, 2013, 123( 5): 1902- 1910. DOI: 10.1172/JCI66369.
    [5]
    ZHANG JQ, WU CX, GAO L, et al. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects[J]. Adv Pharmacol, 2020, 87: 89- 112. DOI: 10.1016/bs.apha.2019.08.002.
    [6]
    HUANG SW, SHAO XH, ZHANG X, et al. Effects of astragaloside IV on low-glucose mediated tumor immunosuppression microenvironment and its mechanism[J]. Chin J Clin Pharmacol Ther, 2024, 29( 11): 1201- 1211. DOI: 10.12092/j.issn.1009-2501.2024.11.001.

    黄仕文, 邵晓寒, 张雪, 等. 黄芪甲苷Ⅳ干预低糖介导的肿瘤免疫抑制微环境作用及其机制研究[J]. 中国临床药理学与治疗学, 2024, 29( 11): 1201- 1211. DOI: 10.12092/j.issn.1009-2501.2024.11.001.
    [7]
    LIANG XY, HONG FF, YANG SL. Astragaloside IV alleviates liver inflammation, oxidative stress and apoptosis to protect against experimental non-alcoholic fatty liver disease[J]. Diabetes Metab Syndr Obes, 2021, 14: 1871- 1883. DOI: 10.2147/DMSO.S304817.
    [8]
    ZHANG C, LI LL, HOU S, et al. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways[J]. J Ethnopharmacol, 2021, 279: 114350. DOI: 10.1016/j.jep.2021.114350.
    [9]
    CHEN HX, CAI JY, WANG JC, et al. Targeting Nestin+ hepatic stellate cells ameliorates liver fibrosis by facilitating TβRI degradation[J]. J Hepatol, 2021, 74( 5): 1176- 1187. DOI: 10.1016/j.jhep.2020.11.016.
    [10]
    YAN MY, CUI YM, XIANG Q. Metabolism of hepatic stellate cells in chronic liver diseases: Emerging molecular and therapeutic interventions[J]. Theranostics, 2025, 15( 5): 1715- 1740. DOI: 10.7150/thno.106597.
    [11]
    SUN YX, YUAN XY, HU ZH, et al. Harnessing nuclear receptors to modulate hepatic stellate cell activation for liver fibrosis resolution[J]. Biochem Pharmacol, 2025, 232: 116730. DOI: 10.1016/j.bcp.2024.116730.
    [12]
    HUANG FJ, XIE XX, LIU X, et al. Research progress on the active ingredients of traditional Chinese medicine against hepatic fibrosis by regulating the MAPK signaling pathway[J]. Chin J Hosp Pharm, 2025, 45( 2): 225- 233. DOI: 10.13286/j.1001-5213.2025.02.17.

    黄甫静, 谢星星, 刘学, 等. 中药活性成分调控MAPK信号通路抗肝纤维化的研究进展[J]. 中国医院药学杂志, 2025, 45( 2): 225- 233. DOI: 10.13286/j.1001-5213.2025.02.17.
    [13]
    CHEN SP, KANG RD, HONG XB, et al. Astragaloside IV regulates Snail1 lactylation and acetylation to mediate macrophage polarization and improve myocardial infarction[J]. Chin J Cell Mol Immunol, 2025, 41( 4): 289- 299. DOI: 10.13423/j.cnki.cjcmi.009952.

    陈少鹏, 康儒典, 洪新宝, 等. 黄芪甲苷Ⅳ调控Snail1乳酸化和乙酰化介导巨噬细胞极化改善大鼠心肌梗死[J]. 细胞与分子免疫学杂志, 2025, 41( 4): 289- 299. DOI: 10.13423/j.cnki.cjcmi.009952.
    [14]
    LI HL, WANG P, HUANG F, et al. Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice[J]. Toxicol Appl Pharmacol, 2018, 340: 58- 66. DOI: 10.1016/j.taap.2017.12.019.
    [15]
    QING LY, LIU LT, XU QP, et al. Astragaloside IV attenuates pathological myocardial hypertrophy and fibrosis in mice via EGR1-SIRT1-PPARα-SCAD signaling pathway[J]. Chin Pharmacol Bull, 2025, 41( 2): 242- 250. DOI: 10.12360/CPB202406092.

    卿丽媛, 刘兰婷, 徐庆萍, 等. 黄芪甲苷Ⅳ基于EGR1-SIRT1-PPARα-SCAD信号通路减轻小鼠病理性心肌肥厚及纤维化[J]. 中国药理学通报, 2025, 41( 2): 242- 250. DOI: 10.12360/CPB202406092.
    [16]
    SHAMSAN E, ALMEZGAGI M, GAMAH M, et al. The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: A comprehensive review[J]. Front Med, 2024, 11: 1389329. DOI: 10.3389/fmed.2024.1389329.
    [17]
    WU C, HUANG L, MO LQ, et al. Anti-fibrotic effects of salvianolate on hepatic fibrosis in rats by regulating TGF-β1/Smad and PI3K/AKT/mTOR signaling pathway[J]. Chin J Hosp Pharm, 2019, 39( 7): 670- 675. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.07.04.

    吴灿, 黄亮, 莫立乾, 等. 丹参多酚酸盐通过TGF-β1/Smad和PI3K/AKT/mTOR信号通路抑制大鼠肝纤维化的进展[J]. 中国医院药学杂志, 2019, 39( 7): 670- 675. DOI: 10.13286/j.cnki.chinhosppharmacyj.2019.07.04.
    [18]
    WEI LW, CHEN QS, GUO AJ, et al. Asiatic acid attenuates CCl4-induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways[J]. Int Immunopharmacol, 2018, 60: 1- 8. DOI: 10.1016/j.intimp.2018.04.016.
    [19]
    AKKıZ H, GIESELER RK, CANBAY A. Liver fibrosis: From basic science towards clinical progress, focusing on the central role of hepatic stellate cells[J]. Int J Mol Sci, 2024, 25( 14): 7873. DOI: 10.3390/ijms25147873.
    [20]
    BAI XY, ZHANG X, HAI L, et al. Regulatory effect and mechanism of macrophage polarization in liver fibrosis[J]. J Clin Hepatol, 2024, 40( 3): 611- 615. DOI: 10.12449/JCH240329.

    白小洋, 张旭, 海龙, 等. 巨噬细胞极化在肝纤维化中的调控作用机制[J]. 临床肝胆病杂志, 2024, 40( 3): 611- 615. DOI: 10.12449/JCH240329.
    [21]
    GAO YY, ZHAN XY, ZHOU HM. The role of endoplasmic reticulum stress in regulating macrophage immune response in liver diseases[J]. Organ Transpl, 2024, 15( 6): 889- 894. DOI: 10.3969/j.issn.1674-7445.2024144.

    高逸云, 詹欣雨, 周浩明. 内质网应激调控巨噬细胞免疫应答在肝脏疾病中的作用[J]. 器官移植, 2024, 15( 6): 889- 894. DOI: 10.3969/j.issn.1674-7445.2024144.
    [22]
    WANG LP, HUANG Y, CHEN JR, et al. Dynamic crosstalk between HSCs and liver microenvironment: Multicellular interactions in the regulation of liver fibrosis[J]. Front Cell Dev Biol, 2025, 13: 1635763. DOI: 10.3389/fcell.2025.1635763.
    [23]
    DUFFIELD JS, FORBES SJ, CONSTANDINOU CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair[J]. J Clin Invest, 2005, 115( 1): 56- 65. DOI: 10.1172/JCI22675.
    [24]
    FENG M, DING J, WANG M, et al. Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution[J]. Int J Biol Sci, 2018, 14( 9): 1033- 1040. DOI: 10.7150/ijbs.25589.
    [25]
    NI J, HONG XD, JI K, et al. Influence of hepatitis B combined with hepatic fibrosis on endogenous and exogenous metabolism and therapeutic implications[J]. Chin J Clin Pharmacol Ther, 2024, 29( 8): 853- 860. DOI: 10.12092/j.issn.1009-2501.2024.08.002.

    倪姐, 洪小丹, 计可, 等. 乙肝合并肝纤维化对内外源性代谢的影响及治疗学启示[J]. 中国临床药理学与治疗学, 2024, 29( 8): 853- 860. DOI: 10.12092/j.issn.1009-2501.2024.08.002.
    [26]
    SUGIMOTO A, SAITO Y, WANG GX, et al. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3[J]. Nature, 2025, 640( 8059): 752- 761. DOI: 10.1038/s41586-025-08677-w.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (33) PDF downloads(12) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return